Publications

Publications - Abstract

R.Bissonnette, R. Haydey, L.A. Rosoph, C.W. Lynde, M. Bukhalo, J.F. Fowler, I. Delorme, A. Gagne'-Henley, M. Gooderham, Y. Poulin, K. Barber, P.

Jenkin, I. Landells, D.M. Pariser 2017. Apremilast for the treatment of moderate to severe palmoplantar psoriasis: results from a double-blind, placebo controlled, randomized study Journal: Journal of the European Academy of Dermatology and Venereology

Salama, S., and P. Jenkin. 1998. Angiomatosis with Intravascular Immunoglobulin Deposits; a case report with immunohistochemical correlation. Orlando, Florida — International Society of Dermatopathology.

Salama, S., and P. Jenkin. 1997. Angioendotheliomatosis associated with luminal cryoprotein deposition; a case report with immunohistochemical correlation. Washington — Awareness of Dermatopathologist.

Roberts, J., Stead, R., Rosenthal, D., Tadros, A., Jenkin, P., Berger, C., Edelson, R. and Sauder, D.N. BEI and BE2 monoclonal Antibody Reactivity in Cutaneous T Cell Lymphoma. J. of Invest. Dermatol. Vol. 82:No. 4, April, 1984.

Angiomatosis of skin with local intravascular immunoglobulin deposits associated with monoclonal gammopathy. A potential cutaneous marker of B-chronic lymphocytic leukemia. J. of Cutaneous Pathology 1999; 26:206-212

REVISED
January 02, 2019

Clinical Research

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Severe or Very Severe Alopecia Areata
(Eli Lilly JAHO)

A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa
(Janssen CNT01959HDS2001)

A 24-Week Multicenter, Randomized, Double-Blind, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis
(Eli Lilly RHCR)

A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of Mirikizumab in Patients with Moderate-to-Severe Plaque Psoriasis OASIS-3
(Eli Lilly AMAH)

A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of BMS-986165 in Subjects with Moderate-to-Severe Plaque Psoriasis
(Bristol Myers Squibb)

A Multicenter, Randomized, Open-label, Phase 3 Long-term Safety Study of Topically Applied Sofpironium Bromide (BBI-4000) Gel, 5% and 15% in Subjects with Axillary Hyperhidrosis
(Brickell Biotech, Inc.)

A Phase 3 Randomized Withdrawal, Double-Blind, Placebo-Controlled, Multi-Center Study Investigating the Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over, with Moderate to Severe Atopic Dermatitis with the Option of Rescue Treatment in Flaring Subjects
(Pfizer)

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab and Placebo in Patients with Moderate-to-Severe Plaque Psoriasis OASIS-2
(Eli Lilly AMAJ)

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis
(Dermira)

Corrona Psoriasis (PSO) Registry

A Phase 3, Double-Blind, Vehicle-Controlled, Randomized, Parallel Group, Multicenter, Efficacy and Safety Study of KX2-391 Ointment 1% in Adult Subjects with Actinic Keratosis on the Face or Scalp
(Athenex KX01-AK-004)

Tralokinumab monotherapy for moderate to severe atopic dermatitis
(Leo Pharma LP0162-1325)

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Tradipitant in Treatment-Resistant Pruritus Associated with Atopic Dermatitis
(Vanda VP-VLY-686-2102)

A Phase 3, Multicenter, Randomized, Double-blind Study Evaluating the Comparative Efficacy of CNTO 1959 (Guselkumab) and Sekukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis
(Janssen CNT01959PS03009)

A multicentre, open Label study to assess the safety and efficacy of risankizuMab for MaInTenance in moderate to severe plaque type Psoriasis
(LIMMITLESS) (AbbVie M15-997)

A 52-week, multicentre, randomized, double-blind study of secukinumab (300 mg) to demonstrate efficacy as assessed by Psoriasis Area and Severity Index and Investigator's Global Assessment after 12 weeks of treatment, compared to ustekinumab, and to assess long-term safety, tolerability, and efficacy in subjects with moderate to severe plaque psoriasis
(CLARITY) (Novartis)

Protocol 16T-MC-AMAF A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo-Controlled Study of LY3074828 in Subjects with Moderate-to-Severe Plaque Psoriasis
(Eli Lilly AMAF)

AbbVie/BI 655066/ABBV-066 (risankizumab) versus adalimumab in randomized, double blind, parallel group trial in Moderate to severe plaque psoriasis to assess safety and efficacy after 13 weeks of treatment and after inadequate adalimumab treatment response
(IMMvent) (AbbVie / Boehringer Ingelheim)

An Open-Label, Long-Term Extension Study to Evaluate the Safety of Cortexolone 17a-Propionate (CB-03-01) Cream, 1% Applied Twice Daily in Subjects with Acne Vulgaris
(Cassiopea LTE)

A Phase 2B Randomizd, Double-Blind, Placebo-Controlled, Parallel, Multicenter, Dose-ranging, Study to Evaluate the Efficacy and Safety Profile of PF-04965842 in Subjects with Moderate to Severe Atopic Dermatitis
(Pfizer)

A Multicenter, Randomized, Double-Blind, Parallel-Group Vehicle Controlled Study to Compare the Efficacy and Safety of CD5789 50vg/g Cream versus Vehicle Cream In Subjects with Acne Vulgaris
(Galderma)

Study 200583: A Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream Administered Once Daily for the Treatment of Plaque Psoriasis
(GlaxoSmithKline)

Study 200704: A Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream Administered Once Daily for the Treatment of Atopic Dermatitis
(GlaxoSmithKline)

A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17a-Propionate (CB-03-01) Cream, 1% Applied Twice Daily for 12 Weeks in Subjects with Facial Acne Vulgaris
(Cassiopea)

A Double-Blind, Placebo-Controlled, Randomized Study on the Safety and Efficacy of Apremilast in Patients with Moderate to Severe Plaque Psoriasis Involving Palms and/or Soles
(Innovaderm)

A Double-Blind, Randomized, Placebo-Controlled, Parallel-Controlled, Two-Center, Phase lib Clinical Trial to Evaluate the Efficacy and Safety of TC cream in Treating Patients with Psoriasis Vulgaris
(PRIG)

A Double-Blind, Randomized, Parallel-Group, Vehicle-Controlled, Multicenter Study to Evaluate the Safety and Bioequivalence of a Generic Pimecrolimus Cream, 1% and Reference Listed Elidel® (Pimecrolimus Cream, 1%) and Compare Both Active Treatments to a Vehicle Control in the Treatment of Mild to Moderate Atopic Dermatitis
(Symbio)

A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Ixekizumab Dosing Regimens in Patients with Moderate to Severe Plaque Psoriasis
(Eli Lilly)

An Open-Label Study Assessing Long-Term Safety of DRM04 in Subjects with Primary Axillary Hyperhidrosis
(Dermira)

A Phase 3, Randomized, Double-Blind, Vehicle-Controlled Efficacy and Safety Study of DRM04 in Subjects with Axillary Hyperhidrosis
(Dermira)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of Multiple Dupilumab Dose Regimens Administered as Monotherapy for Maintaining Treatment Response in Patients with Atopic Dermatitis
(Regeneron)

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety and Efficacy of PF04965843 in Patients with Moderate to Severe Psoriasis
(Pfizer)

A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients with Moderate-to-Severe Atopic Dermatitis
(Regeneron)

A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab for the Treatment of Subjects with Moderate to Severe Plaque type Psoriasis with Randomized Withdrawal and Retreatment VOYAGE 2
(Janssen)

A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults with Moderate to Severe Atopic Dermatitis Treated with Dupilumab
(Regeneron)

A Prospective, Observational Study to Estimate the Proportion of Subjects with Plaque Psoriasis who Achieve Complete Clearance on Biologics
(Amgen)

An Open-Label Study of Dupilumab in patients with Atopic Dermatitis who participated in previous Dupilumab Clinical Trials
(Regeneron)

A Phase 2, Randomized, Double-Blind, Multicenter, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Dose Levels of XP23829 in Subjects with Moderate to Severe Chronic Plaque-Type Psoriasis
(Xenoport)

A Double-Blind, Randomized, parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 versus Enbrel® in Subjects with Chronic Plaque Psoriasis
(CHS-0214-04) (RaPsOdy) (Coherus)

A 52-week, multicenter, randomized, double-blind study of subcutaneous secukinumaB to demonstrate efficacy as assessed by Psoriasis Area and Severity Index at 16 weeks of treatment compared to ustekinumab and to assess long-term safety, tolerability and efficacy in subjects with moderate to severe plaque psoriasis
(Novartis)

A Phase 2, Randomized, Double-Blind, Vehicle Controlled, Comparator Study of the Effect of DRMO4B and DRM04 in Subjects with Axillary Hyperhidrosis
(Dermira)

A Prospective, Observational Study to Estimate the proportion of subjects with Plaque Psoriasis who Achieve complete clearance on Biologics
(Amgen)

A Safety and Efficacy Study to Compare Dapsone Dermal Gel with Vehicle Control in Patients with Acne Vulgaris
(Allergan)

A Phase 2, Randomized, Double-Blind, Vehicle Controlled, Dose-Ranging Study of the Effect of DRMO4B in Subject with Axillary Hyperhidrosis
(Dermira)

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetic and Biomarker Profiles of Dupilumab (REGN668_ Administered to Adult Patient with Moderate-to-Severe Atopic Dermatitis
(Regeneron)

A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severe Hidradenitis Suppurativa
(AbbVie)

A Phase 3 Open-Label Study of the Safety and Efficacy of Adalimumab in Subject with Moderate to Severe Hidradenitis Suppurativa
(AbbVie)

Pharmacokinetic Evaluations of Ixekizumab following Subcutaneous Administration Using Prefilled Syringe or Auto Injector in Patient with Moderate-to-Severe Plaque Psoriasis
(Lilly)

A Randomized, Vehicle-Controlled, Double-Blind, Parallel Group, Multi-Center Phase III Study to Evaluate the Safety and Efficacy of M518101 in Subjects with Plaque Psoriasis
(Maruho)

A Phase 3b, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Double-Dummy, Study of the Efficacy and Safety of Apremilast (CC-10004), Etanercept, and Placebo, in Subjects with Moderate to Severe Plaque Psoriasis
(Celgene)

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2b Study of LY3009104 in Patients with Moderate-to-Severe Plaque Psoriasis
(Lilly)

A Prospective, Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients
(Genentech)

A randomized, double-blind, vehicle-controlled, multicenter, parallel-group clinical trial to assess the safety and efficacy of Azelaic Acid Foam, 15% topically applied twice daily for 12 weeks in patients with papulopustular rosacea
(Bayer)

A Phase 3 randomized, double-blind, 12-week vehicle-controlled, parallel-group study assessing the efficacy and safety of CD5024 I % cream versus vehicle cream in subjects with papulopustular rosacea, followed by a 40-week investigator-blinded extension comparing the long-term safety of CD5024 1% cream versus azelaic acid 15 % gel
(Galderma)

A Randomized, Multi-Center, Double-Blind, Vehicle-Controlled Study Evaluating the Efficacy and Safety of Product 33525 in Subjects with Tinea Cruris
(Medicis)

An Open-Label Study to Evaluate the Safety of Long-Term Administration of Product 33525 in Subjects with Tinea Pedis, Tinea Corporis, or Tinea Cruris
(Medicis)

A Study to Examine the Equivalency of the Paper and Electronic Versions of the Psoriasis Symptom Inventory
(PSI) (Amgen) Cognitive Interviews with Subjects Having Moderate to Severe Chronic Plaque Psoriasis to Assess Injection Instructions
(Merck)

A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects with Moderate to Severe Plaque Psoriasis: AMAGINE-2
(Amgen)

A Multicenter Study with a Randomized, Double-Blind, Placebo=Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long-Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients with Moderate-to-Severe Plaque Psoriasis
(Lilly)

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects with Moderate to Severe Plaque Psoriasis
(Celgene)

A Phase3, Multi-Center, Open-Label Continuation Study in Moderate to Severe Chronic Plaque Psoriasis Subjects who Completed a Preceding Psoriasis Study with ABT-874
(Abbott)

A Randomized, Double-Blind, Placebo-Controlled, Phase Ila Study of the Clinical Activity, Safety. and Tolerability of SRT2104 in Subjects with Moderate to Severe Plaque-Type Psoriasis
(Sirtris)

Phase III: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects with Moderate to Severe Chronic Plaque Psoriasis
(Abbott)

Laser Genesis for the treatment of Toe Nail Fungus
(Cutera) Laser Genesis for the treatment of Fresh Surgical Scars (Cutera) Laser Genesis for the treatment of Rosacea
(Cutera)

Laser Genesis for the treatment of Skin Texture
(Cutera)

Laser Genesis for the treatment of Hyper-pigmentation
(Cutera)

A Phase 3, Multi-Center, Open Label, Continuation Study in Moderate to Severe Chronic Plaque Psoriasis Subjects who Completed a Preceding Psoriasis Study
(Abbott)

A 10-Year, Post-Marketing, Observational, Registry of HUMIRAO (Adalimumab) in Adult Patients with Chronic Plaque Psoriasis
(Abbott)

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Etanercept in Treating Scalp Involvement in Subjects with Moderate to Severe Plaque Psoriasis
(Amgen)

Observational Post-Marketing Safety Surveillance Registry of Enbrel® (etanercept) for the Treatment of Psoriasis
(Amgen)

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Adding Methotrexate to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis
(Amgen)

An Open-label Extension Study to Evaluate the Safety of Etanercept in Pediatric Subjects with Plaque Psoriasis,
(Amgen)

Assessment and Tracking of Long-term Alefacept (LFA-3/1gG I Fusion Protein) Safety
(ATLAS) (Astellas)

A Prospective Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Tacrolimus Ointment for the Treatment of Atopic Dermatitis (Astellas)

A Phase 2B, Multicenter, Treatment-Arm Blind, Safety and Efficacy 28-week Extension Study of Apremilast in Subjects who Completed the Treatment Phase of the Core Study
(Celgene)

A Multicenter International Observational Study of the Long-term Safety of Infliximab
(REMICADE®) (Centocor)

A Multicenter, Open Registry of Patients with Psoriasis Who Are Candidates for Systemic Therapy Including Biologics
(Centocor)

A Phase 3, Multicenter, Randomized, Double-blind, Placebo controlled Trial Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Subjects with Moderate to Severe Plaque-type Psoriasis
(Centocor)

A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
(GlaxoSmithKline)

REVISED
January 02, 2019